Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

TENX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Tenax Therapeutics, Inc.NASDAQ: TENX

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$16.57M, compared with -$11.34M a year earlier. Trailing-twelve-month operating income was -$61.62M.

Context

  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -189.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.57M-0.8% QoQ
Last fiscal yearDec 2025
-$56.39M-189.2% YoY
LTMMar 2026
-$61.62M-248.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.2%+100.0%+146.2 pp
1 year-189.2%+100.0%+289.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(56.39M) USD
Year-over-year change
-189.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How TENX compares with its peers on the latest reported figures

  • TENX's LTM Mar 2026 operating income of -$61.62M is the 6th highest of the 7 companies compared; the peer median is -$36.13M.
  • Its year-over-year change of -248.4% is the lowest of 7, against a peer median of +21.7%.
TENX Competitors Peer median
Operating Income for TENX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$21.41M +133.7%—39.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$13.52M +75.6%—36.4%
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$35.14M -117.4%——
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$37.12M +25.8%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$60.69M +17.7%——
TENXTenax Therapeutics, Inc.LTM Mar 2026-$61.62M -248.4%——
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$71.82M -71.7%——
Peer median (excluding TENX) -$36.13M+21.7%—38.1%

Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development25.15M5.38M3.23M12.71M32.67M
Selling, General & Admin7.58M5.68M5.01M6.79M23.71M
Operating Expenses32.73M11.05M8.23M19.49M56.39M
Depreciation & Amortization108.98K113.33K8K00
EBITDA(32.36M)(10.93M)(7.68M)(17.58M)(52.6M)
EBITDA Margin—————
Operating Income(32.73M)(11.05M)(8.23M)(19.49M)(56.39M)
Operating Margin—————
Interest Income0001.91M3.82M
Interest Expense9494.44K23.97K23K0
Other Income / Expenses253.88K4.75K523K1.89M3.79M
Income Before Tax(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Net Margin—————
EPS (Basic)(2,524.80)(600.80)(31.09)(1.15)(1.34)
EPS (Diluted)(2,524.80)(600.80)(31.04)(1.15)(1.34)
Weighted Avg Shares12.86K18.39K248K15.27M39.22M
Weighted Avg Shares (Diluted)12.86K18.39K248.45K15.27M39.22M

Tenax Therapeutics, Inc.

NASDAQ:TENX

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.